Hyperactivity Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

This Phase 4 study tested SPN-812, a medication already approved for ADHD, focusing on adults who also experience mood symptoms like irritability or low mood. The trial, now completed, examined how safe and effective SPN-812 is when used in real-world settings with flexible dosing. For adults managing ADHD and mood challenges, these results may support another treatment option that could help control symptoms with potentially improved tolerability.

Digital Therapy for Treating Attention Deficit Hyperactivity Disorder

This trial explored a digital, game-based therapy designed to improve attention and behavior in children with ADHD. Conducted in China with 40 children, the study tested a non-drug approach that could make effective treatment more accessible in schools, especially those with fewer resources. Results are still pending, but if positive, this could offer a new way to support children with ADHD without medication.

Personalizing Psychosocial Intervention for Children With Disruptive Behaviour

This study focused on children with disruptive behavior disorders, using personalized behavioral parent training tailored to each child’s psychological and emotional needs. With 600 children involved, the goal was to improve how well treatments work by matching them more closely to individual profiles. Results are pending, but this approach could mean better support for children and families dealing with challenging behaviors.

Magnetoencephalography in Children

This ongoing study is using a brain imaging technique called magnetoencephalography to better understand brain activity in children with neurodevelopmental disorders. Although not focused solely on hyperactivity, this research may improve diagnosis of conditions like ADHD by locating brain abnormalities more precisely. The study is recruiting children in China and could lead to better tailored treatments in the future.

Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

This trial is testing a workshop-based program for adults with both ADHD and substance use disorder in prison settings. By improving care coordination and offering integrated treatments, the study aims to support better management of these complex conditions. Recruitment is ongoing in France, and the approach may offer new ways to help people facing multiple challenges in difficult environments.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report for Hyperactivity this week. Get weekly briefings at trialsalert.com.